BACKGROUND: Hyperhomocysteinemia is associated with cerebral small vessel disease (SVD). We examined the relationship between homocysteine and 1) volumetric measure of white matter change (WMC), 2) silent brain infarcts, 3) cerebral atrophy on MRI and 4) cognition on a consecutive cohort of patients with stroke associated with SVD. SUBJECTS AND METHODS: Fifty-seven patients consecutively admitted to the Acute Stroke Unit in a university hospital due to stroke associated with SVD were recruited and assessed three months after the stroke. Non-fasting homocysteine was obtained. Using MRI, the number of infarcts, volume of WMC and cerebral atrophy were measured. General cognitive functions were assessed using the Mini Mental State Examination and Alzheimer's disease Assessment Scale. Mattis Dementia Rating Scale - Initiation/Perseveration subset was used to assess executive cognitive functions. RESULTS: Hyperhomocysteinemia (> or = 14.88 micromol/L) significantly accounted for the volume of WMC on MRI in a multivariate stepwise regression model (adjusted R(2)=0.058, p <0.05) after adjustment for age and folate level. Patients in the highest quartile of WMC volume had significantly higher levels of homocysteine than those in lowest quartile (p <0.001). No significant relationship was found between homocysteine and silent brain infarcts, cerebral atrophy and performance on psychometric tests. CONCLUSION: Hyperhomocysteinemia is associated with volumetric measure of WMC among patients with SVD. The role of homocysteine in the development of silent brain infarcts and cerebral atrophy as previously reported cannot be ascertained in this study. No direct relationship was found between homocysteine and cognitive functions.
BACKGROUND:Hyperhomocysteinemia is associated with cerebral small vessel disease (SVD). We examined the relationship between homocysteine and 1) volumetric measure of white matter change (WMC), 2) silent brain infarcts, 3) cerebral atrophy on MRI and 4) cognition on a consecutive cohort of patients with stroke associated with SVD. SUBJECTS AND METHODS: Fifty-seven patients consecutively admitted to the Acute Stroke Unit in a university hospital due to stroke associated with SVD were recruited and assessed three months after the stroke. Non-fasting homocysteine was obtained. Using MRI, the number of infarcts, volume of WMC and cerebral atrophy were measured. General cognitive functions were assessed using the Mini Mental State Examination and Alzheimer's disease Assessment Scale. Mattis Dementia Rating Scale - Initiation/Perseveration subset was used to assess executive cognitive functions. RESULTS:Hyperhomocysteinemia (> or = 14.88 micromol/L) significantly accounted for the volume of WMC on MRI in a multivariate stepwise regression model (adjusted R(2)=0.058, p <0.05) after adjustment for age and folate level. Patients in the highest quartile of WMC volume had significantly higher levels of homocysteine than those in lowest quartile (p <0.001). No significant relationship was found between homocysteine and silent brain infarcts, cerebral atrophy and performance on psychometric tests. CONCLUSION:Hyperhomocysteinemia is associated with volumetric measure of WMC among patients with SVD. The role of homocysteine in the development of silent brain infarcts and cerebral atrophy as previously reported cannot be ascertained in this study. No direct relationship was found between homocysteine and cognitive functions.
Authors: T Pohjasvaara; M Leskelä; R Vataja; H Kalska; R Ylikoski; M Hietanen; A Leppävuori; M Kaste; T Erkinjuntti Journal: Eur J Neurol Date: 2002-05 Impact factor: 6.089
Authors: K S Woo; P Chook; Y I Lolin; A S Cheung; L T Chan; Y Y Sun; J E Sanderson; C Metreweli; D S Celermajer Journal: Circulation Date: 1997-10-21 Impact factor: 29.690
Authors: T Matsui; H Arai; T Yuzuriha; H Yao; M Miura; S Hashimoto; S Higuchi; S Matsushita; M Morikawa; A Kato; H Sasaki Journal: Stroke Date: 2001-05 Impact factor: 7.914
Authors: V C T Mok; A Wong; W W M Lam; Y H Fan; W K Tang; T Kwok; A C F Hui; K S Wong Journal: J Neurol Neurosurg Psychiatry Date: 2004-04 Impact factor: 10.154
Authors: Dana R Jorgensen; C Elizabeth Shaaban; Clayton A Wiley; Peter J Gianaros; Joseph Mettenburg; Caterina Rosano Journal: Am J Physiol Heart Circ Physiol Date: 2018-02-02 Impact factor: 4.733
Authors: Auriel A Willette; Catherine Gallagher; Barbara B Bendlin; Donald G McLaren; Erik K Kastman; Elisa Canu; Kris J Kosmatka; Aaron S Field; Andrew L Alexander; Ricki J Colman; Mary-Lou L Voytko; Richard H Weindruch; Christopher L Coe; Sterling C Johnson Journal: Neurobiol Aging Date: 2010-08-05 Impact factor: 4.673
Authors: Andrew T Jacovina; Arunkumar B Deora; Qi Ling; M Johan Broekman; Dena Almeida; Caroline B Greenberg; Aaron J Marcus; Jonathan D Smith; Katherine A Hajjar Journal: J Clin Invest Date: 2009-10-19 Impact factor: 14.808
Authors: Sudha Seshadri; Philip A Wolf; Alexa S Beiser; Jacob Selhub; Rhoda Au; Paul F Jacques; Mitsuhiro Yoshita; Irwin H Rosenberg; Ralph B D'Agostino; Charles DeCarli Journal: Arch Neurol Date: 2008-05
Authors: Y Ohshima; T Mizuno; K Yamada; S Matsumoto; Y Nagakane; M Kondo; N Kuriyama; T Miyazaki; K Takeda; T Nishimura; M Nakagawa; K Ozasa; Y Watanabe Journal: J Nutr Health Aging Date: 2013 Impact factor: 4.075